Analysts Are Gushing Over The Meet Group, Inc. (MEET), Nektar Therapeutics (NKTR)

The Meet Group, Inc. (NASDAQ:MEET) last session’s volume of 1.35 million shares was lower than its average volume of 1.37 million shares. The stock, after opening at $2.94, hit $2.82 through the close by scoring -5.05%.

The Meet Group, Inc. (MEET) Analyst Opinion

The Meet Group, Inc. has a consensus outperform rating from 4 Wall Street analysts, and the number of shares currently sold short amount to at least 10% of shares outstanding. The stock spiked 11.02% last month and is down -42.8 this year. Wall Street is only getting more bullish on the stock, with 2 of analysts who cover MEET having a buy-equivalent rating. Analysts have placed a $4.5 price target on The Meet Group, Inc., suggesting a 59.57% gain from recent close. It’s currently trading about -56.28% below its 52-week high.

The Meet Group, Inc. Earnings Surprise

The Meet Group, Inc. (MEET) revenue totaled $32.33 million up 3.19% from the previous quarter.

The Meet Group, Inc. (NASDAQ:MEET) Intraday View

This stock (MEET) is ahead of its 52-week low with 28.77%. Its last month’s stock price volatility remained 6.08% which for the week stands at 6.61%. The share price has moved forward from its 20 days moving average, trading at a distance of 9.68% and stays 0.02% away from its 50 days moving average. Over the last five days, shares have faced -8.14% losses and now is down -33.27% since hitting its 200-day moving average of $3.73. The Meet Group, Inc. (MEET) has made its way to a 12-month decline of -44.16%.

Turning to Nektar Therapeutics (NASDAQ:NKTR), its shares were trading at $59.72 a retreat of $-0.78, on the trading floor. The stock, after opening at $60.8, touched a high of $60.979 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.7. Nektar Therapeutics has 4 buy ratings, 1 holds and 0 sells even after the stock tumbled -3.49% from its high of $61.88 to a $9.34 billion market value through last close.

Nektar Therapeutics (NKTR) Consensus Price Target

The company’s consensus rating on Reuter’s scale slipped from 1.7 to 1.67 during a month. Analysts set a 12-month price target of $39 a share. The target implies a -34.7% decrease from where the shares are currently trading. Also, the current price highlights a discount of -16.28% to analysts’ high consensus price target.

Nektar Therapeutics (NASDAQ:NKTR) Intraday Trading

The counter witnessed a trading volume of 1.48 million shares versus an average volume of 2.28 million shares during last trading session. Its last month’s stock price volatility remained 4.03% which for the week approaches 4.88%. The lowest price the stock reached in the last trading day was $59.65 and compares with the $11.41 52-week low. The stock recovered 423.4% since its low point and has performed 386.72% year-to-date.

SHARE
Previous articleStreet Analysts View On RH (RH), DelMar Pharmaceuticals, Inc. (DMPI)
Next articleAnalysts Give These Stocks Mix Nod: Blue Apron Holdings, Inc. (APRN), Spectrum Pharmaceuticals, Inc. (SPPI)